Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Белок Klotho, фактор роста фибробластов 23 и склеростин при хронической сердечной недостаточности: обзор литературы
Белок Klotho, фактор роста фибробластов 23 и склеростин при хронической сердечной недостаточности: обзор литературы
Алиева А.М., Резник Е.В., Котикова И.А., Никитин И.Г. Белок Klotho, фактор роста фибробластов 23 и склеростин при хронической сердечной недостаточности: oбзор литературы. CardioСоматика // 2024.
Т. 15, № 1. С. 41–53. DOI: https://doi.org/10.17816/CS625473
Т. 15, № 1. С. 41–53. DOI: https://doi.org/10.17816/CS625473
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Хроническая сердечная недостаточность (ХСН) является глобальной медицинской, социальной и экономической проблемой. ХСН — это синдром, обусловленный дисбалансом нейрогуморальной регуляции сердечно-сосудистой системы, который сопровождается нарушением систолической и/или диастолической функции сердца. В настоящее время продолжаются поиск и изучение новых биологических маркёров, способных обеспечить раннюю диагностику ХСН, служить лабораторным инструментом для оценки эффективности проводящегося лечения или использоваться в качестве прогностических маркёров и критериев стратификации риска. Интерес исследователей сосредоточен на изучении роли белка Klotho, фактора роста фибробластов 23 (FGF23) и склеростина у пациентов с ХСН. Интенсивность экспрессии Klotho уменьшается по мере старения организма, дефекты его выработки были зарегистрированы при различных заболеваниях, ассоциированных со старением. Ось FGF23 / Klotho играет ключевую регуляторную роль при кардиоваскулярной патологии. Триангуляция данных лабораторных, клинических и генетических исследований позволяет предположить, что склеростин связан с заболеваниями сердца, хотя полученные к настоящему времени данные не вполне согласуются друг с другом. Проведённые клинические исследования, посвящённые изучению белка Klotho, FGF-23 и склеростина, указывают на потенциально важную диагностическую и прогностическую значимость их анализа у пациентов с ХСН. Вопросы, связанные с серийным тестированием этих биологических маркёров, в том числе и в аспекте мультибиомаркёрной модели, нуждаются в дальнейшем изучении.
Ключевые слова: биологические маркёры, сердечно-сосудистые заболевания, белок Klotho, фактор роста фибробластов 23, склеростин
Keywords: biological markers, cardiovascular diseases, Klotho protein, fibroblast growth factor 23, sclerostin
Ключевые слова: биологические маркёры, сердечно-сосудистые заболевания, белок Klotho, фактор роста фибробластов 23, склеростин
________________________________________________
Keywords: biological markers, cardiovascular diseases, Klotho protein, fibroblast growth factor 23, sclerostin
Полный текст
Список литературы
1. Riccardi M., Sammartino A., Piepoli M., et al. Heart failure: an update from the last years and a look at the near future // ESC Heart Fail. 2022. Vol. 9, N 6. P. 3667–3693.
doi: 10.1002/ehf2.14257. Erratum in: ESC Heart Fail. 2023. Vol. 10, N 3. P. 2143.
2. Голухова Е.З., Алиева А.М. Клиническое значение определения натрийуретических пептидов у больных с хронической сердечной недостаточностью // Кардиология и сердечнососудистая хирургия. 2007. № 1. С. 45–51. EDN: HGTYXS
3. Bozkurt B., Coats A., Tsutsui H., et al. Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure// J Card Fail. 2021. S1071‑9164(21)00050-6.
doi: 10.1016/j.cardfail.2021.01.022. Epub ahead of print.
4. Szlagor M., Dybiec J., Młynarska E., et al. Chronic Kidney Disease as a Comorbidity in Heart Failure // Int J Mol Sci. 2023. Vol. 24, N 3. P. 2988. doi: 10.3390/ijms24032988
5. Голухова Е.З., Теряева Н.Б., Алиева А.М. Натрийуретические пептиды — маркеры и факторы прогноза при хронической сердечной недостаточности // Креативная кардиология. 2007. № 1–2. C. 126–136. EDN: KAOPTV
6. Kuro-o M., Matsumura Y., Aizawa H., et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing // Nature. 1997. Vol. 390, N 6655. P. 45–51. doi: 10.1038/36285
7. Алиева А.М., Резник Е.В., Теплова Н.В., и др. Белок Klotho и атеросклеротические сердечно-сосудистые заболевания: продлевая нить жизни // Российский медицинский журнал. 2022. Т. 28, № 5. С. 365–380. doi: 10.17816/medjrf110823
8. Liu Y., Chen M. Emerging role of α-Klotho in energy metabolism and cardiometabolic diseases // Diabetes Metab Syndr. 2023. Vol. 17, N 10. P. 102854. doi: 10.1016/j.dsx.2023.102854
9. Prud'homme G., Kurt M., Wang Q. Pathobiology of the Klotho Antiaging Protein and Therapeutic Considerations // Front Aging. 2022. N 3. P. 931331. doi: 10.3389/fragi.2022.931331
10. Tobias J. Sclerostin and Cardiovascular Disease // Curr Osteoporos Rep. 2023. Vol. 21, N 5. P. 519–526. doi: 10.1007/s11914-023-00810-w
11. Olejnik A., Franczak A., Krzywonos-Zawadzka A., et al. The Biological Role of Klotho Protein in the Development of Cardiovascular Diseases // Biomed Res Int. 2018. N 2018.
P. 5171945. doi: 10.1155/2018/5171945. Erratum in: Biomed Res Int. 2020. N 2020. P. 1463925.
12. Алиева А.М., Пинчук Т.В., Кисляков В.А., и др. Фактор роста фибробластов (FGF23) — новый биологический маркер при сердечной недостаточности // Кремлевская медицина. Клинический вестник. 2022. № 1. С. 59–65. doi: 10.26269/pygh-k050
13. Kuro-O M. The Klotho proteins in health and disease // Nat Rev Nephrol. 2019. Vol. 15, N 1. P. 27–44. doi: 10.1038/s41581-018-0078-3
14. Thomas S., Li Q., Faul C. Fibroblast growth factor 23, klotho and heparin // Curr Opin Nephrol Hypertens. 2023. Vol. 32, N 4. P. 313–323. doi: 10.1097/MNH.0000000000000895
15. Chen G., Liu Y., Goetz R., et al. α-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signaling // Nature. 2018. Vol. 553, N 7689. P. 461–466. doi: 10.1038/nature25451
16. Ranjbar N., Raeisi M., Barzegar M., et al. The possible anti-seizure properties of Klotho // Brain Res. 2023. N 1820. P. 148555. doi: 10.1016/j.brainres.2023.148555
17. Masuda H., Chikuda H., Suga T., et al. Regulation of multiple ageing-like phenotypes by inducible klotho gene expression in klotho mutant mice // Mech Ageing Dev. 2005. Vol. 126,
N 12. P. 1274–1283. doi: 10.1016/j.mad.2005.07.007
18. Espuch-Oliver A., Vazquez-Lorente H., Jurado-Fasoli L., et al. References Values of Soluble α-Klotho Serum Levels Using an Enzyme-Linked Immunosorbent Assay in Healthy Adults Aged 18–85 Years // J Clin Med. 2022. Vol. 11, N 9. P. 2415. doi: 10.3390/jcm11092415
19. Kresovich J., Bulka C. Low serum klotho associated with all-cause mortality among a nationally representative sample of American adults // J Gerontol A Biol Sci Med Sci. 2022.
Vol. 3, N 3. P. 452–456. doi: 10.1093/gerona/glab308
20. Li L., Liu W., Mao Q., et al. Klotho Ameliorates Vascular Calcification via Promoting Autophagy // Oxid Med Cell Longev. 2022. N 2022. P. 7192507. doi: 10.1155/2022/7192507
21. Mencke R., Hillebrands J; NIGRAM consortium. The role of the anti-ageing protein Klotho in vascular physiology and pathophysiology// Ageing Res Rev. 2017. N 35. P. 124–146.
doi: 10.1016/j.arr.2016.09.001
22. Wang Y., Wang K., Bao Y., et al. The serum soluble Klotho alleviates cardiac aging and regulates M2a/M2c macrophage polarization via inhibiting TLR4/Myd88/NF-κB pathway // Tissue Cell. 2022. N 76. P. 101812. doi: 10.1016/j.tice.2022.101812
23. Li X., Zhai Y., Yao Q., et al. Up-regulation of Myocardial Klotho Expression to Promote Cardiac Functional Recovery in Old Mice following Endotoxemia // Res Sq [Preprint]. 2023. rs.3.rs-2949854. doi: 10.21203/rs.3.rs-2949854/v1
24. Ding J., Tang Q., Luo B., et al. Klotho inhibits angiotensin II‑induced cardiac hypertrophy, fibrosis, and dysfunction in mice through suppression of transforming growth factor-β1 signaling pathway// Eur J Pharmacol. 2019. N 859. P. 172549. doi: 10.1016/j.ejphar.2019.172549
25. Wang K., Li Z., Li Y., et al. Cardioprotection of Klotho against myocardial infarction-induced heart failure through inducing autophagy// Mech Ageing Dev. 2022. N 207. P. 111714.
doi: 10.1016/j.mad.2022.111714
26. Kamel S., Baky N., Karkeet R., et al. Astaxanthin extenuates the inhibition of aldehyde dehydrogenase and Klotho protein expression in cyclophosphamide-induced acute cardiomyopathic rat model // Clin Exp Pharmacol Physiol. 2022. Vol. 49, N 2. P. 291–301. doi: 10.1111/1440-1681.13598
27. Zhuang X., Sun X., Zhou H., et al. Klotho attenuated Doxorubicin-induced cardiomyopathy by alleviating Dynamin-related protein 1-mediated mitochondrial dysfunction // Mech Ageing Dev. 2021. N 195. P. 111442. doi: 10.1016/j.mad.2021.111442
28. Chen W. Soluble Alpha-Klotho Alleviates Cardiac Fibrosis without Altering Cardiomyocytes Renewal // Int J Mol Sci. 2020. Vol. 21, N 6. P. 2186. doi: 10.3390/ijms21062186
29. Xiong X., Wang G., Wang Y., et al. Klotho protects against aged myocardial cells by attenuating ferroptosis // Exp Gerontol. 2023. N 175. P. 112157. doi: 10.1016/j.exger.2023.112157
30. Cai J., Zhang L., Chen C., et al. Association between serum Klotho concentration and heart failure in adults, a cross-sectional study from NHANES 2007-2016 // Int J Cardiol. 2023.
N 370. P. 236–243. doi: 10.1016/j.ijcard.2022.11.010
31. Luo W., Wei N., Sun Z., Gong Y. Association between serum α-klotho level and the prevalence of heart failure in the general population // Cardiovasc J Afr. 2023. N 34. P. 1–6.
doi: 10.5830/CVJA-2023-042. Epub ahead of print.
32. Mora-Fernandez C., Perez A., Mollar A., et al. Short-term changes in klotho and FGF23 in heart failure with reduced ejection fraction-a substudy of the DAPA-VO2 study // Front Cardiovasc Med. 2023. N 10. P. 1242108. doi: 10.3389/fcvm.2023.1242108
33. Nakano T., Kishimoto H., Tokumoto M. Direct and indirect effects of fibroblast growth factor 23 on the heart // Front Endocrinol (Lausanne). 2023. N 14. P. 1059179.
doi: 10.3389/fendo.2023.1059179
34. Agoro R., White K. Regulation of FGF23 production and phosphate metabolism by bone-kidney interactions // Nat Rev Nephrol. 2023. Vol. 19, N 3. P. 185–193.
doi: 10.1038/s41581-022-00665-x
35. Garcia-Fernandez N., Lavilla J., Martín P., et al. Increased fibroblast growth factor 23 in heart failure: biomarker, mechanism, or both? // Am J Hypertens. 2019. Vol. 32, N 1. P. 15–17. doi: 10.1093/ajh/hpy153
36. Ho B., Bergwitz C. FGF23 signalling and physiology // J Mol Endocrinol. 2022. Vol. 66, N 2. P. R23–R32. doi: 10.1530/JME-20-0178
37. Suzuki Y., Kuzina E., An S., et al. FGF23 contains two distinct high-affinity binding sites enabling bivalent interactions with α-Klotho // Proc Natl Acad Sci U S A. 2020. Vol. 117, N 50.
P. 31800–31807. doi: 10.1073/pnas.2018554117
38. Cipriani C., Minisola S., Colangelo L., et al. FGF23 functions and disease // Minerva Endocrinol (Torino). 2022. Vol. 47, N 4. P. 437–448. doi: 10.23736/S2724-6507.21.03378-2
39. Dastghaib S., Koohpeyma F., Shams M., et al. New concepts in regulation and function of the FGF23 // Clin Exp Med. 2023. Vol. 23, N 4. P. 1055–1066.
doi: 10.1007/s10238-022-00844-x
40. Leifheit-Nestler M., Haffner D. Paracrine Effects of FGF23 on the Heart // Front Endocrinol (Lausanne). 2018. N 9. P. 278. doi: 10.3389/fendo.2018.00278
41. Grabner A., Amaral A., Schramm K., et al. Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy // Cell Metab. 2015. Vol. 22, N 6.
P. 1020–1032. doi: 10.1016/j.cmet.2015.09.002
42. Liu M., Xia P., Tan Z., et al. Fibroblast growth factor-23 and the risk of cardiovascular diseases and mortality in the general population: A systematic review and dose-response meta-analysis // Front Cardiovasc Med. 2022. N 9. P. 989574. doi: 10.3389/fcvm.2022.989574
43. Vergaro G., Del Franco A., Aimo A., et al. Intact fibroblast growth factor 23 in heart failure with reduced and mildly reduced ejection fraction // BMC Cardiovasc Disord. 2023. Vol. 23, N 1. P. 433. doi: 10.1186/s12872-023-03441-2
44. von Jeinsen B., Sopova K., Palapies L., et al. Bone marrow and plasma FGF-23 in heart failure patients: novel insights into the heart-bone axis // ESC Heart Fail. 2019. Vol. 6, N 3.
P. 536–544. doi: 10.1002/ehf2.12416
45. Elzayat R., Bahbah W., Elzaiat R., Elgazzar B. Fibroblast growth factor 23 in children with or without heart failure: a prospective study // BMJ Paediatr Open. 2023. Vol. 7, N 1.
P. e001753. doi: 10.1136/bmjpo-2022-001753
46. Roy C., Lejeune S., Slimani A., et al. Fibroblast growth factor 23: a biomarker of fibrosis and prognosis in heart failure with preserved ejection fraction // ESC Heart Fail. 2020. Vol. 7,
N 5. P. 2494–2507. doi: 10.1002/ehf2.12816
47. Hofer F., Hammer A., Pailer U., et al. Relationship of Fibroblast Growth Factor 23 With Hospitalization for Heart Failure and Cardiovascular Outcomes in Patients Undergoing Cardiac Surgery // J Am Heart Assoc. 2023. Vol. 12, N 5. P. 027875. doi: 10.1161/JAHA.122.027875
48. Binnenmars S., Hoogslag G., Yeung S., et al. Fibroblast Growth Factor 23 and Risk of New Onset Heart Failure with Preserved or Reduced Ejection Fraction: The PREVEND Study // J Am Heart Assoc. 2022. Vol. 11, N 15. P. e024952. doi: 10.1161/JAHA.121.024952
49. Oniszczuk A., Kaczmarek A., Kaczmarek M., et al. Sclerostin as a biomarker of physical exercise in osteoporosis: A narrative review // Front Endocrinol (Lausanne). 2022. N 13.
P. 954895. doi: 10.3389/fendo.2022.954895
50. Jaśkiewicz Ł., Chmielewski G., Kuna J., et al. The Role of Sclerostin in Rheumatic Diseases: A Review // J Clin Med. 2023. Vol. 12, N 19. P. 6248. doi: 10.3390/jcm12196248
51. Sanabria-de la Torre R., González-Salvatierra S., Garcia-Fontana C., et al. Exploring the Role of Sclerostin as a Biomarker of Cardiovascular Disease and Mortality: A Scoping Review // Int J Environ Res Public Health. 2022. Vol. 19, N 23. P. 15981. doi: 10.3390/ijerph192315981
52. Vasiliadis E., Evangelopoulos D., Kaspiris A., et al. Sclerostin and Its Involvement in the Pathogenesis of Idiopathic Scoliosis // J Clin Med. 2021. Vol. 10, N 22. P. 5286.
doi: 10.3390/jcm10225286
53. Maeda K., Kobayashi Y., Koide M., et al. The Regulation of Bone Metabolism and Disorders by Wnt Signaling // Int J Mol Sci. 2019. Vol. 20, N 22. P. 5525. doi: 10.3390/ijms20225525
54. Tu X., Delgado-Calle J., Condon K.W., et al. Osteocytes mediate the anabolic actions of canonical Wnt/β-catenin signaling in bone // Proc Natl Acad Sci U S A. 2015. Vol. 112, N 5.
P. E478–E486. doi: 10.1073/pnas.1409857112
55. Daniele G., Winnier D., Mari A., et al. Sclerostin and Insulin Resistance in Prediabetes: Evidence of a Cross Talk Between Bone and Glucose Metabolism // Diabetes Care. 2015.
Vol. 38, N 8. P. 1509–1517. doi: 10.2337/dc14-2989
56. Matsui S., Yasui T., Kasai K., et al. Increase in Circulating Sclerostin at the Early Stage of Menopausal Transition in Japanese Women // Maturitas. 2016. N 83. P. 72–77.
doi: 10.1016/j.maturitas.2015.10.001
57. Mackey R., Venkitachalam L., Sutton-Tyrrell K. Calcifications, Arterial Stiffness and Atherosclerosis// Adv Cardiol. 2007. N 44. P. 234–244. doi: 10.1159/000096744
58. Sabancilar I., Unsal V., Demir F., et al. Does oxidative status affect serum sclerostin levels in patients with type 2 diabetes mellitus? // Folia Med (Plovdiv). 2023. Vol. 65, N 1. P. 46–52. doi: 10.3897/folmed.65.e72953
59. Golledge J., Thanigaimani S. Role of sclerostin in cardiovascular disease // Arterioscler Thromb Vasc Biol. 2022. Vol. 42, N 7. P. e187–e202. doi: 10.1161/ATVBAHA.122.317635
60. Frysz M., Gergei I., Scharnagl H., et al. Circulating Sclerostin Levels Are Positively Related to Coronary Artery Disease Severity and Related Risk Factors // J Bone Miner Res. 2022. Vol. 37, N 2. P. 273–284. doi: 10.1002/jbmr.4467
2. Golukhova EZ, Alieva AM. Clinical value of natriuretic peptides detection at the patients with chronic heart failure. Kardiologiya i Serdechno-Sosudistaya Khirurgiya. 2007;(1):45–51. EDN: HGTYXS
3. Bozkurt B, Coats AJ, Tsutsui H, et al. Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. J Card Fail. 2021:S1071‑9164(21)00050-6.
doi: 10.1016/j.cardfail.2021.01.022. Epub ahead of print.
4. Szlagor M, Dybiec J, Młynarska E, et al. Chronic Kidney Disease as a Comorbidity in Heart Failure. Int J Mol Sci. 2023;24(3):2988. doi: 10.3390/ijms24032988
5. Golukhova EZ, Teryaeva NB, Alieva AM. Natriuretic peptides — markers and prognosis factors in chronic heart failure. Creative Cardiology. 2007;(1–2):126–136. (In Russ.) EDN: KAOPTV
6. Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390(6655):45–51. doi: 10.1038/36285
7. Alieva AM, Reznik EV, Teplova NV, et al. Klotho protein and atherosclerotic cardiovascular diseases: prolonging the thread of life. Russian Medicine. 2022;28(5):365–380.
doi: 10.17816/medjrf110823
8. Liu Y, Chen M. Emerging role of α-Klotho in energy metabolism and cardiometabolic diseases. Diabetes Metab Syndr. 2023;17(10):102854. doi: 10.1016/j.dsx.2023.102854
9. Prud'homme GJ, Kurt M, Wang Q. Pathobiology of the Klotho Antiaging Protein and Therapeutic Considerations. Front Aging. 2022;(3):931331. doi: 10.3389/fragi.2022.931331
10. Tobias JH. Sclerostin and Cardiovascular Disease. Curr Osteoporos Rep. 2023;21(5):519–526. doi: 10.1007/s11914-023-00810-w
11. Olejnik A, Franczak A, Krzywonos-Zawadzka A, et al. The Biological Role of Klotho Protein in the Development of Cardiovascular Diseases. Biomed Res Int. 2018;(2018):5171945.
doi: 10.1155/2018/5171945. Erratum in: Biomed Res Int. 2020;(2020):1463925.
12. Alieva AM, Pinchuk TV, Kislyakov VA, et al. Fibroblast growth factor-23 (fgf23) is a novel biological marker in heart failure. KMJ. 2022;(1):59–65. doi: 10.26269/pygh-k050
13. Kuro-O M. The Klotho proteins in health and disease. Nat Rev Nephrol. 2019;15(1):27–44. doi: 10.1038/s41581-018-0078-3
14. Thomas SM, Li Q, Faul C. Fibroblast growth factor 23, klotho and heparin. Curr Opin Nephrol Hypertens. 2023;32(4):313–323. doi: 10.1097/MNH.0000000000000895
15. Chen G, Liu Y, Goetz R, et al. α-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signalling. Nature. 2018;553(7689):461–466. doi: 10.1038/nature25451
16. Ranjbar N, Raeisi M, Barzegar M, et al. The possible anti-seizure properties of Klotho. Brain Res. 2023;(1820):148555. doi: 10.1016/j.brainres.2023.148555
17. Masuda H, Chikuda H, Suga T, et al. Regulation of multiple ageing-like phenotypes by inducible klotho gene expression in klotho mutant mice. Mech Ageing Dev.
2005;126(12):1274–1283. doi: 10.1016/j.mad.2005.07.007
18. Espuch-Oliver A, Vázquez-Lorente H, Jurado-Fasoli L, et al. References Values of Soluble α-Klotho Serum Levels Using an Enzyme-Linked Immunosorbent Assay in Healthy Adults Aged 18–85 Years. J Clin Med. 2022;11(9):2415. doi: 10.3390/jcm11092415
19. Kresovich JK, Bulka CM. Low Serum Klotho Associated With All-cause Mortality Among a Nationally Representative Sample of American Adults. J Gerontol A Biol Sci Med Sci. 2022;77(3):452–456. doi: 10.1093/gerona/glab308
20. Li L, Liu W, Mao Q, et al. Klotho Ameliorates Vascular Calcification via Promoting Autophagy. Oxid Med Cell Longev. 2022;(2022):7192507. doi: 10.1155/2022/7192507
21. Mencke R, Hillebrands JL; NIGRAM consortium. The role of the anti-ageing protein Klotho in vascular physiology and pathophysiology. Ageing Res Rev. 2017;(35):124–146.
doi: 10.1016/j.arr.2016.09.001
22. Wang Y, Wang K, Bao Y, et al. The serum soluble Klotho alleviates cardiac aging and regulates M2a/M2c macrophage polarization via inhibiting TLR4/Myd88/NF-κB pathway. Tissue Cell. 2022;(76):101812. doi: 10.1016/j.tice.2022.101812
23. Li X, Zhai Y, Yao Q, et al. Up-regulation of Myocardial Klotho Expression to Promote Cardiac Functional Recovery in Old Mice following Endotoxemia. Res Sq [Preprint].
2023:rs.3.rs-2949854. doi: 10.21203/rs.3.rs-2949854/v1
24. Ding J, Tang Q, Luo B, et al. Klotho inhibits angiotensin II-induced cardiac hypertrophy, fibrosis, and dysfunction in mice through suppression of transforming growth factor-β1 signaling pathway. Eur J Pharmacol. 2019;(859):172549. doi: 10.1016/j.ejphar.2019.172549
25. Wang K, Li Z, Li Y, et al. Cardioprotection of Klotho against myocardial infarction-induced heart failure through inducing autophagy. Mech Ageing Dev. 2022;(207):111714.
doi: 10.1016/j.mad.2022.111714
26. Kamel SS, Baky NAA, Karkeet RM, et al. Astaxanthin extenuates the inhibition of aldehyde dehydrogenase and Klotho protein expression in cyclophosphamide-induced acute cardiomyopathic rat model. Clin Exp Pharmacol Physiol. 2022;49(2):291–301. doi: 10.1111/1440-1681.13598
27. Zhuang X, Sun X, Zhou H, et al. Klotho attenuated Doxorubicin-induced cardiomyopathy by alleviating Dynamin-related protein 1-mediated mitochondrial dysfunction. Mech Ageing Dev. 2021;(195):111442. doi: 10.1016/j.mad.2021.111442
28. Chen WY. Soluble Alpha-Klotho Alleviates Cardiac Fibrosis without Altering Cardiomyocytes Renewal. Int J Mol Sci. 2020;21(6):2186. doi: 10.3390/ijms21062186
29. Xiong X, Wang G, Wang Y, et al. Klotho protects against aged myocardial cells by attenuating ferroptosis. Exp Gerontol. 2023;(175):112157. doi: 10.1016/j.exger.2023.112157
30. Cai J, Zhang L, Chen C, et al. Association between serum Klotho concentration and heart failure in adults, a cross-sectional study from NHANES 2007-2016. Int J Cardiol.
2023;(370):236–243. doi: 10.1016/j.ijcard.2022.11.010
31. Luo W, Wei N, Sun Z, Gong Y. Association between serum α-klotho level and the prevalence of heart failure in the general population. Cardiovasc J Afr. 2023;(34):1–6.
doi: 10.5830/CVJA-2023-042. Epub ahead of print.
32. Mora-Fernández C, Pérez A, Mollar A, et al. Short-term changes in klotho and FGF23 in heart failure with reduced ejection fraction-a substudy of the DAPA-VO2 study. Front Cardiovasc Med. 2023;(10):1242108. doi: 10.3389/fcvm.2023.1242108
33. Nakano T, Kishimoto H, Tokumoto M. Direct and indirect effects of fibroblast growth factor 23 on the heart. Front Endocrinol (Lausanne). 2023;(14):1059179.
doi: 10.3389/fendo.2023.1059179
34. Agoro R, White KE. Regulation of FGF23 production and phosphate metabolism by bone-kidney interactions. Nat Rev Nephrol. 2023;19(3):185–193.
doi: 10.1038/s41581-022-00665-x
35. Garcia-Fernandez N, Lavilla J, Martín PL, et al. Increased Fibroblast Growth Factor 23 in Heart Failure: Biomarker, Mechanism, or Both? Am J Hypertens. 2019;32(1):15–17.
doi: 10.1093/ajh/hpy153
36. Ho BB, Bergwitz C. FGF23 signalling and physiology. J Mol Endocrinol. 2021;66(2):R23–R32. doi: 10.1530/JME-20-0178
37. Suzuki Y, Kuzina E, An SJ, et al. FGF23 contains two distinct high-affinity binding sites enabling bivalent interactions with α-Klotho. Proc Natl Acad Sci U S A.
2020;117(50):31800–31807. doi: 10.1073/pnas.2018554117
38. Cipriani C, Minisola S, Colangelo L, et al. FGF23 functions and disease. Minerva Endocrinol (Torino). 2022;47(4):437–448. doi: 10.23736/S2724-6507.21.03378-2
39. Dastghaib S, Koohpeyma F, Shams M, et al. New concepts in regulation and function of the FGF23. Clin Exp Med. 2023;23(4):1055–1066. doi: 10.1007/s10238-022-00844-x
40. Leifheit-Nestler M, Haffner D. Paracrine Effects of FGF23 on the Heart. Front Endocrinol (Lausanne). 2018;(9):278. doi: 10.3389/fendo.2018.00278
41. Grabner A, Amaral AP, Schramm K, et al. Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy. Cell Metab. 2015;22(6):1020–1032.
doi: 10.1016/j.cmet.2015.09.002
42. Liu M, Xia P, Tan Z, et al. Fibroblast growth factor-23 and the risk of cardiovascular diseases and mortality in the general population: A systematic review and dose-response meta-analysis. Front Cardiovasc Med. 2022;(9):989574. doi: 10.3389/fcvm.2022.989574
43. Vergaro G, Del Franco A, Aimo A, et al. Intact fibroblast growth factor 23 in heart failure with reduced and mildly reduced ejection fraction. BMC Cardiovasc Disord. 2023;23(1):433. doi: 10.1186/s12872-023-03441-2
44. von Jeinsen B, Sopova K, Palapies L, et al. Bone marrow and plasma FGF-23 in heart failure patients: novel insights into the heart-bone axis. ESC Heart Fail. 2019;6(3):536–544.
doi: 10.1002/ehf2.12416
45. Elzayat RS, Bahbah WA, Elzaiat RS, Elgazzar BA. Fibroblast growth factor 23 in children with or without heart failure: a prospective study. BMJ Paediatr Open. 2023;7(1):e001753.
doi: 10.1136/bmjpo-2022-001753
46. Roy C, Lejeune S, Slimani A, et al. Fibroblast growth factor 23: a biomarker of fibrosis and prognosis in heart failure with preserved ejection fraction. ESC Heart Fail.
2020;7(5):2494–2507. doi: 10.1002/ehf2.12816
47. Hofer F, Hammer A, Pailer U, et al. Relationship of Fibroblast Growth Factor 23 With Hospitalization for Heart Failure and Cardiovascular Outcomes in Patients Undergoing Cardiac Surgery. J Am Heart Assoc. 2023;12(5):e027875. doi: 10.1161/JAHA.122.027875
48. Binnenmars SH, Hoogslag GE, Yeung SMH, et al. Fibroblast Growth Factor 23 and Risk of New Onset Heart Failure With Preserved or Reduced Ejection Fraction: The PREVEND Study. J Am Heart Assoc. 2022;11(15):e024952. doi: 10.1161/JAHA.121.024952
49. Oniszczuk A, Kaczmarek A, Kaczmarek M, et al. Sclerostin as a biomarker of physical exercise in osteoporosis: A narrative review. Front Endocrinol (Lausanne). 2022;(13):954895. doi: 10.3389/fendo.2022.954895
50. Jaśkiewicz Ł, Chmielewski G, Kuna J, et al. The Role of Sclerostin in Rheumatic Diseases: A Review. J Clin Med. 2023;12(19):6248. doi: 10.3390/jcm12196248
51. Sanabria-de la Torre R, González-Salvatierra S, García-Fontana C, et al. Exploring the Role of Sclerostin as a Biomarker of Cardiovascular Disease and Mortality: A Scoping Review. Int J Environ Res Public Health. 2022;19(23):15981. doi: 10.3390/ijerph192315981
52. Vasiliadis ES, Evangelopoulos DS, Kaspiris A, et al. Sclerostin and Its Involvement in the Pathogenesis of Idiopathic Scoliosis. J Clin Med. 2021;10(22):5286.
doi: 10.3390/jcm10225286
53. Maeda K, Kobayashi Y, Koide M, et al. The Regulation of Bone Metabolism and Disorders by Wnt Signaling. Int J Mol Sci. 2019;20(22):5525. doi: 10.3390/ijms20225525
54. Tu X, Delgado-Calle J, Condon KW, et al. Osteocytes mediate the anabolic actions of canonical Wnt/β-catenin signaling in bone. Proc Natl Acad Sci U S A. 2015;112(5):E478–E486. doi: 10.1073/pnas.1409857112
55. Daniele G, Winnier D, Mari A, et al. Sclerostin and Insulin Resistance in Prediabetes: Evidence of a Cross Talk Between Bone and Glucose Metabolism. Diabetes Care. 2015;38(8):1509–1517. doi: 10.2337/dc14-2989
56. Matsui S, Yasui T, Kasai K, et al. Increase in circulating sclerostin at the early stage of menopausal transition in Japanese women. Maturitas. 2016;(83):72–77.
doi: 10.1016/j.maturitas.2015.10.001
57. Mackey RH, Venkitachalam L, Sutton-Tyrrell K. Calcifications, arterial stiffness and atherosclerosis. Adv Cardiol. 2007;(44):234–244. doi: 10.1159/000096744
58. Sabancilar I, Unsal V, Demir F, et al. Does oxidative status affect serum sclerostin levels in patients with type 2 diabetes mellitus? Folia Med (Plovdiv). 2023;65(1):46–52.
doi: 10.3897/folmed.65.e72953
59. Golledge J, Thanigaimani S. Role of Sclerostin in Cardiovascular Disease. Arterioscler Thromb Vasc Biol. 2022;42(7):e187–e202. doi: 10.1161/ATVBAHA.122.317635
60. Frysz M, Gergei I, Scharnagl H, et al. Circulating Sclerostin Levels Are Positively Related to Coronary Artery Disease Severity and Related Risk Factors. J Bone Miner Res. 2022;37(2):273–284. doi: 10.1002/jbmr.4467
doi: 10.1002/ehf2.14257. Erratum in: ESC Heart Fail. 2023. Vol. 10, N 3. P. 2143.
2. Голухова Е.З., Алиева А.М. Клиническое значение определения натрийуретических пептидов у больных с хронической сердечной недостаточностью // Кардиология и сердечнососудистая хирургия. 2007. № 1. С. 45–51. EDN: HGTYXS
3. Bozkurt B., Coats A., Tsutsui H., et al. Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure// J Card Fail. 2021. S1071‑9164(21)00050-6.
doi: 10.1016/j.cardfail.2021.01.022. Epub ahead of print.
4. Szlagor M., Dybiec J., Młynarska E., et al. Chronic Kidney Disease as a Comorbidity in Heart Failure // Int J Mol Sci. 2023. Vol. 24, N 3. P. 2988. doi: 10.3390/ijms24032988
5. Голухова Е.З., Теряева Н.Б., Алиева А.М. Натрийуретические пептиды — маркеры и факторы прогноза при хронической сердечной недостаточности // Креативная кардиология. 2007. № 1–2. C. 126–136. EDN: KAOPTV
6. Kuro-o M., Matsumura Y., Aizawa H., et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing // Nature. 1997. Vol. 390, N 6655. P. 45–51. doi: 10.1038/36285
7. Алиева А.М., Резник Е.В., Теплова Н.В., и др. Белок Klotho и атеросклеротические сердечно-сосудистые заболевания: продлевая нить жизни // Российский медицинский журнал. 2022. Т. 28, № 5. С. 365–380. doi: 10.17816/medjrf110823
8. Liu Y., Chen M. Emerging role of α-Klotho in energy metabolism and cardiometabolic diseases // Diabetes Metab Syndr. 2023. Vol. 17, N 10. P. 102854. doi: 10.1016/j.dsx.2023.102854
9. Prud'homme G., Kurt M., Wang Q. Pathobiology of the Klotho Antiaging Protein and Therapeutic Considerations // Front Aging. 2022. N 3. P. 931331. doi: 10.3389/fragi.2022.931331
10. Tobias J. Sclerostin and Cardiovascular Disease // Curr Osteoporos Rep. 2023. Vol. 21, N 5. P. 519–526. doi: 10.1007/s11914-023-00810-w
11. Olejnik A., Franczak A., Krzywonos-Zawadzka A., et al. The Biological Role of Klotho Protein in the Development of Cardiovascular Diseases // Biomed Res Int. 2018. N 2018.
P. 5171945. doi: 10.1155/2018/5171945. Erratum in: Biomed Res Int. 2020. N 2020. P. 1463925.
12. Алиева А.М., Пинчук Т.В., Кисляков В.А., и др. Фактор роста фибробластов (FGF23) — новый биологический маркер при сердечной недостаточности // Кремлевская медицина. Клинический вестник. 2022. № 1. С. 59–65. doi: 10.26269/pygh-k050
13. Kuro-O M. The Klotho proteins in health and disease // Nat Rev Nephrol. 2019. Vol. 15, N 1. P. 27–44. doi: 10.1038/s41581-018-0078-3
14. Thomas S., Li Q., Faul C. Fibroblast growth factor 23, klotho and heparin // Curr Opin Nephrol Hypertens. 2023. Vol. 32, N 4. P. 313–323. doi: 10.1097/MNH.0000000000000895
15. Chen G., Liu Y., Goetz R., et al. α-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signaling // Nature. 2018. Vol. 553, N 7689. P. 461–466. doi: 10.1038/nature25451
16. Ranjbar N., Raeisi M., Barzegar M., et al. The possible anti-seizure properties of Klotho // Brain Res. 2023. N 1820. P. 148555. doi: 10.1016/j.brainres.2023.148555
17. Masuda H., Chikuda H., Suga T., et al. Regulation of multiple ageing-like phenotypes by inducible klotho gene expression in klotho mutant mice // Mech Ageing Dev. 2005. Vol. 126,
N 12. P. 1274–1283. doi: 10.1016/j.mad.2005.07.007
18. Espuch-Oliver A., Vazquez-Lorente H., Jurado-Fasoli L., et al. References Values of Soluble α-Klotho Serum Levels Using an Enzyme-Linked Immunosorbent Assay in Healthy Adults Aged 18–85 Years // J Clin Med. 2022. Vol. 11, N 9. P. 2415. doi: 10.3390/jcm11092415
19. Kresovich J., Bulka C. Low serum klotho associated with all-cause mortality among a nationally representative sample of American adults // J Gerontol A Biol Sci Med Sci. 2022.
Vol. 3, N 3. P. 452–456. doi: 10.1093/gerona/glab308
20. Li L., Liu W., Mao Q., et al. Klotho Ameliorates Vascular Calcification via Promoting Autophagy // Oxid Med Cell Longev. 2022. N 2022. P. 7192507. doi: 10.1155/2022/7192507
21. Mencke R., Hillebrands J; NIGRAM consortium. The role of the anti-ageing protein Klotho in vascular physiology and pathophysiology// Ageing Res Rev. 2017. N 35. P. 124–146.
doi: 10.1016/j.arr.2016.09.001
22. Wang Y., Wang K., Bao Y., et al. The serum soluble Klotho alleviates cardiac aging and regulates M2a/M2c macrophage polarization via inhibiting TLR4/Myd88/NF-κB pathway // Tissue Cell. 2022. N 76. P. 101812. doi: 10.1016/j.tice.2022.101812
23. Li X., Zhai Y., Yao Q., et al. Up-regulation of Myocardial Klotho Expression to Promote Cardiac Functional Recovery in Old Mice following Endotoxemia // Res Sq [Preprint]. 2023. rs.3.rs-2949854. doi: 10.21203/rs.3.rs-2949854/v1
24. Ding J., Tang Q., Luo B., et al. Klotho inhibits angiotensin II‑induced cardiac hypertrophy, fibrosis, and dysfunction in mice through suppression of transforming growth factor-β1 signaling pathway// Eur J Pharmacol. 2019. N 859. P. 172549. doi: 10.1016/j.ejphar.2019.172549
25. Wang K., Li Z., Li Y., et al. Cardioprotection of Klotho against myocardial infarction-induced heart failure through inducing autophagy// Mech Ageing Dev. 2022. N 207. P. 111714.
doi: 10.1016/j.mad.2022.111714
26. Kamel S., Baky N., Karkeet R., et al. Astaxanthin extenuates the inhibition of aldehyde dehydrogenase and Klotho protein expression in cyclophosphamide-induced acute cardiomyopathic rat model // Clin Exp Pharmacol Physiol. 2022. Vol. 49, N 2. P. 291–301. doi: 10.1111/1440-1681.13598
27. Zhuang X., Sun X., Zhou H., et al. Klotho attenuated Doxorubicin-induced cardiomyopathy by alleviating Dynamin-related protein 1-mediated mitochondrial dysfunction // Mech Ageing Dev. 2021. N 195. P. 111442. doi: 10.1016/j.mad.2021.111442
28. Chen W. Soluble Alpha-Klotho Alleviates Cardiac Fibrosis without Altering Cardiomyocytes Renewal // Int J Mol Sci. 2020. Vol. 21, N 6. P. 2186. doi: 10.3390/ijms21062186
29. Xiong X., Wang G., Wang Y., et al. Klotho protects against aged myocardial cells by attenuating ferroptosis // Exp Gerontol. 2023. N 175. P. 112157. doi: 10.1016/j.exger.2023.112157
30. Cai J., Zhang L., Chen C., et al. Association between serum Klotho concentration and heart failure in adults, a cross-sectional study from NHANES 2007-2016 // Int J Cardiol. 2023.
N 370. P. 236–243. doi: 10.1016/j.ijcard.2022.11.010
31. Luo W., Wei N., Sun Z., Gong Y. Association between serum α-klotho level and the prevalence of heart failure in the general population // Cardiovasc J Afr. 2023. N 34. P. 1–6.
doi: 10.5830/CVJA-2023-042. Epub ahead of print.
32. Mora-Fernandez C., Perez A., Mollar A., et al. Short-term changes in klotho and FGF23 in heart failure with reduced ejection fraction-a substudy of the DAPA-VO2 study // Front Cardiovasc Med. 2023. N 10. P. 1242108. doi: 10.3389/fcvm.2023.1242108
33. Nakano T., Kishimoto H., Tokumoto M. Direct and indirect effects of fibroblast growth factor 23 on the heart // Front Endocrinol (Lausanne). 2023. N 14. P. 1059179.
doi: 10.3389/fendo.2023.1059179
34. Agoro R., White K. Regulation of FGF23 production and phosphate metabolism by bone-kidney interactions // Nat Rev Nephrol. 2023. Vol. 19, N 3. P. 185–193.
doi: 10.1038/s41581-022-00665-x
35. Garcia-Fernandez N., Lavilla J., Martín P., et al. Increased fibroblast growth factor 23 in heart failure: biomarker, mechanism, or both? // Am J Hypertens. 2019. Vol. 32, N 1. P. 15–17. doi: 10.1093/ajh/hpy153
36. Ho B., Bergwitz C. FGF23 signalling and physiology // J Mol Endocrinol. 2022. Vol. 66, N 2. P. R23–R32. doi: 10.1530/JME-20-0178
37. Suzuki Y., Kuzina E., An S., et al. FGF23 contains two distinct high-affinity binding sites enabling bivalent interactions with α-Klotho // Proc Natl Acad Sci U S A. 2020. Vol. 117, N 50.
P. 31800–31807. doi: 10.1073/pnas.2018554117
38. Cipriani C., Minisola S., Colangelo L., et al. FGF23 functions and disease // Minerva Endocrinol (Torino). 2022. Vol. 47, N 4. P. 437–448. doi: 10.23736/S2724-6507.21.03378-2
39. Dastghaib S., Koohpeyma F., Shams M., et al. New concepts in regulation and function of the FGF23 // Clin Exp Med. 2023. Vol. 23, N 4. P. 1055–1066.
doi: 10.1007/s10238-022-00844-x
40. Leifheit-Nestler M., Haffner D. Paracrine Effects of FGF23 on the Heart // Front Endocrinol (Lausanne). 2018. N 9. P. 278. doi: 10.3389/fendo.2018.00278
41. Grabner A., Amaral A., Schramm K., et al. Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy // Cell Metab. 2015. Vol. 22, N 6.
P. 1020–1032. doi: 10.1016/j.cmet.2015.09.002
42. Liu M., Xia P., Tan Z., et al. Fibroblast growth factor-23 and the risk of cardiovascular diseases and mortality in the general population: A systematic review and dose-response meta-analysis // Front Cardiovasc Med. 2022. N 9. P. 989574. doi: 10.3389/fcvm.2022.989574
43. Vergaro G., Del Franco A., Aimo A., et al. Intact fibroblast growth factor 23 in heart failure with reduced and mildly reduced ejection fraction // BMC Cardiovasc Disord. 2023. Vol. 23, N 1. P. 433. doi: 10.1186/s12872-023-03441-2
44. von Jeinsen B., Sopova K., Palapies L., et al. Bone marrow and plasma FGF-23 in heart failure patients: novel insights into the heart-bone axis // ESC Heart Fail. 2019. Vol. 6, N 3.
P. 536–544. doi: 10.1002/ehf2.12416
45. Elzayat R., Bahbah W., Elzaiat R., Elgazzar B. Fibroblast growth factor 23 in children with or without heart failure: a prospective study // BMJ Paediatr Open. 2023. Vol. 7, N 1.
P. e001753. doi: 10.1136/bmjpo-2022-001753
46. Roy C., Lejeune S., Slimani A., et al. Fibroblast growth factor 23: a biomarker of fibrosis and prognosis in heart failure with preserved ejection fraction // ESC Heart Fail. 2020. Vol. 7,
N 5. P. 2494–2507. doi: 10.1002/ehf2.12816
47. Hofer F., Hammer A., Pailer U., et al. Relationship of Fibroblast Growth Factor 23 With Hospitalization for Heart Failure and Cardiovascular Outcomes in Patients Undergoing Cardiac Surgery // J Am Heart Assoc. 2023. Vol. 12, N 5. P. 027875. doi: 10.1161/JAHA.122.027875
48. Binnenmars S., Hoogslag G., Yeung S., et al. Fibroblast Growth Factor 23 and Risk of New Onset Heart Failure with Preserved or Reduced Ejection Fraction: The PREVEND Study // J Am Heart Assoc. 2022. Vol. 11, N 15. P. e024952. doi: 10.1161/JAHA.121.024952
49. Oniszczuk A., Kaczmarek A., Kaczmarek M., et al. Sclerostin as a biomarker of physical exercise in osteoporosis: A narrative review // Front Endocrinol (Lausanne). 2022. N 13.
P. 954895. doi: 10.3389/fendo.2022.954895
50. Jaśkiewicz Ł., Chmielewski G., Kuna J., et al. The Role of Sclerostin in Rheumatic Diseases: A Review // J Clin Med. 2023. Vol. 12, N 19. P. 6248. doi: 10.3390/jcm12196248
51. Sanabria-de la Torre R., González-Salvatierra S., Garcia-Fontana C., et al. Exploring the Role of Sclerostin as a Biomarker of Cardiovascular Disease and Mortality: A Scoping Review // Int J Environ Res Public Health. 2022. Vol. 19, N 23. P. 15981. doi: 10.3390/ijerph192315981
52. Vasiliadis E., Evangelopoulos D., Kaspiris A., et al. Sclerostin and Its Involvement in the Pathogenesis of Idiopathic Scoliosis // J Clin Med. 2021. Vol. 10, N 22. P. 5286.
doi: 10.3390/jcm10225286
53. Maeda K., Kobayashi Y., Koide M., et al. The Regulation of Bone Metabolism and Disorders by Wnt Signaling // Int J Mol Sci. 2019. Vol. 20, N 22. P. 5525. doi: 10.3390/ijms20225525
54. Tu X., Delgado-Calle J., Condon K.W., et al. Osteocytes mediate the anabolic actions of canonical Wnt/β-catenin signaling in bone // Proc Natl Acad Sci U S A. 2015. Vol. 112, N 5.
P. E478–E486. doi: 10.1073/pnas.1409857112
55. Daniele G., Winnier D., Mari A., et al. Sclerostin and Insulin Resistance in Prediabetes: Evidence of a Cross Talk Between Bone and Glucose Metabolism // Diabetes Care. 2015.
Vol. 38, N 8. P. 1509–1517. doi: 10.2337/dc14-2989
56. Matsui S., Yasui T., Kasai K., et al. Increase in Circulating Sclerostin at the Early Stage of Menopausal Transition in Japanese Women // Maturitas. 2016. N 83. P. 72–77.
doi: 10.1016/j.maturitas.2015.10.001
57. Mackey R., Venkitachalam L., Sutton-Tyrrell K. Calcifications, Arterial Stiffness and Atherosclerosis// Adv Cardiol. 2007. N 44. P. 234–244. doi: 10.1159/000096744
58. Sabancilar I., Unsal V., Demir F., et al. Does oxidative status affect serum sclerostin levels in patients with type 2 diabetes mellitus? // Folia Med (Plovdiv). 2023. Vol. 65, N 1. P. 46–52. doi: 10.3897/folmed.65.e72953
59. Golledge J., Thanigaimani S. Role of sclerostin in cardiovascular disease // Arterioscler Thromb Vasc Biol. 2022. Vol. 42, N 7. P. e187–e202. doi: 10.1161/ATVBAHA.122.317635
60. Frysz M., Gergei I., Scharnagl H., et al. Circulating Sclerostin Levels Are Positively Related to Coronary Artery Disease Severity and Related Risk Factors // J Bone Miner Res. 2022. Vol. 37, N 2. P. 273–284. doi: 10.1002/jbmr.4467
________________________________________________
2. Golukhova EZ, Alieva AM. Clinical value of natriuretic peptides detection at the patients with chronic heart failure. Kardiologiya i Serdechno-Sosudistaya Khirurgiya. 2007;(1):45–51. EDN: HGTYXS
3. Bozkurt B, Coats AJ, Tsutsui H, et al. Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. J Card Fail. 2021:S1071‑9164(21)00050-6.
doi: 10.1016/j.cardfail.2021.01.022. Epub ahead of print.
4. Szlagor M, Dybiec J, Młynarska E, et al. Chronic Kidney Disease as a Comorbidity in Heart Failure. Int J Mol Sci. 2023;24(3):2988. doi: 10.3390/ijms24032988
5. Golukhova EZ, Teryaeva NB, Alieva AM. Natriuretic peptides — markers and prognosis factors in chronic heart failure. Creative Cardiology. 2007;(1–2):126–136. (In Russ.) EDN: KAOPTV
6. Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390(6655):45–51. doi: 10.1038/36285
7. Alieva AM, Reznik EV, Teplova NV, et al. Klotho protein and atherosclerotic cardiovascular diseases: prolonging the thread of life. Russian Medicine. 2022;28(5):365–380.
doi: 10.17816/medjrf110823
8. Liu Y, Chen M. Emerging role of α-Klotho in energy metabolism and cardiometabolic diseases. Diabetes Metab Syndr. 2023;17(10):102854. doi: 10.1016/j.dsx.2023.102854
9. Prud'homme GJ, Kurt M, Wang Q. Pathobiology of the Klotho Antiaging Protein and Therapeutic Considerations. Front Aging. 2022;(3):931331. doi: 10.3389/fragi.2022.931331
10. Tobias JH. Sclerostin and Cardiovascular Disease. Curr Osteoporos Rep. 2023;21(5):519–526. doi: 10.1007/s11914-023-00810-w
11. Olejnik A, Franczak A, Krzywonos-Zawadzka A, et al. The Biological Role of Klotho Protein in the Development of Cardiovascular Diseases. Biomed Res Int. 2018;(2018):5171945.
doi: 10.1155/2018/5171945. Erratum in: Biomed Res Int. 2020;(2020):1463925.
12. Alieva AM, Pinchuk TV, Kislyakov VA, et al. Fibroblast growth factor-23 (fgf23) is a novel biological marker in heart failure. KMJ. 2022;(1):59–65. doi: 10.26269/pygh-k050
13. Kuro-O M. The Klotho proteins in health and disease. Nat Rev Nephrol. 2019;15(1):27–44. doi: 10.1038/s41581-018-0078-3
14. Thomas SM, Li Q, Faul C. Fibroblast growth factor 23, klotho and heparin. Curr Opin Nephrol Hypertens. 2023;32(4):313–323. doi: 10.1097/MNH.0000000000000895
15. Chen G, Liu Y, Goetz R, et al. α-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signalling. Nature. 2018;553(7689):461–466. doi: 10.1038/nature25451
16. Ranjbar N, Raeisi M, Barzegar M, et al. The possible anti-seizure properties of Klotho. Brain Res. 2023;(1820):148555. doi: 10.1016/j.brainres.2023.148555
17. Masuda H, Chikuda H, Suga T, et al. Regulation of multiple ageing-like phenotypes by inducible klotho gene expression in klotho mutant mice. Mech Ageing Dev.
2005;126(12):1274–1283. doi: 10.1016/j.mad.2005.07.007
18. Espuch-Oliver A, Vázquez-Lorente H, Jurado-Fasoli L, et al. References Values of Soluble α-Klotho Serum Levels Using an Enzyme-Linked Immunosorbent Assay in Healthy Adults Aged 18–85 Years. J Clin Med. 2022;11(9):2415. doi: 10.3390/jcm11092415
19. Kresovich JK, Bulka CM. Low Serum Klotho Associated With All-cause Mortality Among a Nationally Representative Sample of American Adults. J Gerontol A Biol Sci Med Sci. 2022;77(3):452–456. doi: 10.1093/gerona/glab308
20. Li L, Liu W, Mao Q, et al. Klotho Ameliorates Vascular Calcification via Promoting Autophagy. Oxid Med Cell Longev. 2022;(2022):7192507. doi: 10.1155/2022/7192507
21. Mencke R, Hillebrands JL; NIGRAM consortium. The role of the anti-ageing protein Klotho in vascular physiology and pathophysiology. Ageing Res Rev. 2017;(35):124–146.
doi: 10.1016/j.arr.2016.09.001
22. Wang Y, Wang K, Bao Y, et al. The serum soluble Klotho alleviates cardiac aging and regulates M2a/M2c macrophage polarization via inhibiting TLR4/Myd88/NF-κB pathway. Tissue Cell. 2022;(76):101812. doi: 10.1016/j.tice.2022.101812
23. Li X, Zhai Y, Yao Q, et al. Up-regulation of Myocardial Klotho Expression to Promote Cardiac Functional Recovery in Old Mice following Endotoxemia. Res Sq [Preprint].
2023:rs.3.rs-2949854. doi: 10.21203/rs.3.rs-2949854/v1
24. Ding J, Tang Q, Luo B, et al. Klotho inhibits angiotensin II-induced cardiac hypertrophy, fibrosis, and dysfunction in mice through suppression of transforming growth factor-β1 signaling pathway. Eur J Pharmacol. 2019;(859):172549. doi: 10.1016/j.ejphar.2019.172549
25. Wang K, Li Z, Li Y, et al. Cardioprotection of Klotho against myocardial infarction-induced heart failure through inducing autophagy. Mech Ageing Dev. 2022;(207):111714.
doi: 10.1016/j.mad.2022.111714
26. Kamel SS, Baky NAA, Karkeet RM, et al. Astaxanthin extenuates the inhibition of aldehyde dehydrogenase and Klotho protein expression in cyclophosphamide-induced acute cardiomyopathic rat model. Clin Exp Pharmacol Physiol. 2022;49(2):291–301. doi: 10.1111/1440-1681.13598
27. Zhuang X, Sun X, Zhou H, et al. Klotho attenuated Doxorubicin-induced cardiomyopathy by alleviating Dynamin-related protein 1-mediated mitochondrial dysfunction. Mech Ageing Dev. 2021;(195):111442. doi: 10.1016/j.mad.2021.111442
28. Chen WY. Soluble Alpha-Klotho Alleviates Cardiac Fibrosis without Altering Cardiomyocytes Renewal. Int J Mol Sci. 2020;21(6):2186. doi: 10.3390/ijms21062186
29. Xiong X, Wang G, Wang Y, et al. Klotho protects against aged myocardial cells by attenuating ferroptosis. Exp Gerontol. 2023;(175):112157. doi: 10.1016/j.exger.2023.112157
30. Cai J, Zhang L, Chen C, et al. Association between serum Klotho concentration and heart failure in adults, a cross-sectional study from NHANES 2007-2016. Int J Cardiol.
2023;(370):236–243. doi: 10.1016/j.ijcard.2022.11.010
31. Luo W, Wei N, Sun Z, Gong Y. Association between serum α-klotho level and the prevalence of heart failure in the general population. Cardiovasc J Afr. 2023;(34):1–6.
doi: 10.5830/CVJA-2023-042. Epub ahead of print.
32. Mora-Fernández C, Pérez A, Mollar A, et al. Short-term changes in klotho and FGF23 in heart failure with reduced ejection fraction-a substudy of the DAPA-VO2 study. Front Cardiovasc Med. 2023;(10):1242108. doi: 10.3389/fcvm.2023.1242108
33. Nakano T, Kishimoto H, Tokumoto M. Direct and indirect effects of fibroblast growth factor 23 on the heart. Front Endocrinol (Lausanne). 2023;(14):1059179.
doi: 10.3389/fendo.2023.1059179
34. Agoro R, White KE. Regulation of FGF23 production and phosphate metabolism by bone-kidney interactions. Nat Rev Nephrol. 2023;19(3):185–193.
doi: 10.1038/s41581-022-00665-x
35. Garcia-Fernandez N, Lavilla J, Martín PL, et al. Increased Fibroblast Growth Factor 23 in Heart Failure: Biomarker, Mechanism, or Both? Am J Hypertens. 2019;32(1):15–17.
doi: 10.1093/ajh/hpy153
36. Ho BB, Bergwitz C. FGF23 signalling and physiology. J Mol Endocrinol. 2021;66(2):R23–R32. doi: 10.1530/JME-20-0178
37. Suzuki Y, Kuzina E, An SJ, et al. FGF23 contains two distinct high-affinity binding sites enabling bivalent interactions with α-Klotho. Proc Natl Acad Sci U S A.
2020;117(50):31800–31807. doi: 10.1073/pnas.2018554117
38. Cipriani C, Minisola S, Colangelo L, et al. FGF23 functions and disease. Minerva Endocrinol (Torino). 2022;47(4):437–448. doi: 10.23736/S2724-6507.21.03378-2
39. Dastghaib S, Koohpeyma F, Shams M, et al. New concepts in regulation and function of the FGF23. Clin Exp Med. 2023;23(4):1055–1066. doi: 10.1007/s10238-022-00844-x
40. Leifheit-Nestler M, Haffner D. Paracrine Effects of FGF23 on the Heart. Front Endocrinol (Lausanne). 2018;(9):278. doi: 10.3389/fendo.2018.00278
41. Grabner A, Amaral AP, Schramm K, et al. Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy. Cell Metab. 2015;22(6):1020–1032.
doi: 10.1016/j.cmet.2015.09.002
42. Liu M, Xia P, Tan Z, et al. Fibroblast growth factor-23 and the risk of cardiovascular diseases and mortality in the general population: A systematic review and dose-response meta-analysis. Front Cardiovasc Med. 2022;(9):989574. doi: 10.3389/fcvm.2022.989574
43. Vergaro G, Del Franco A, Aimo A, et al. Intact fibroblast growth factor 23 in heart failure with reduced and mildly reduced ejection fraction. BMC Cardiovasc Disord. 2023;23(1):433. doi: 10.1186/s12872-023-03441-2
44. von Jeinsen B, Sopova K, Palapies L, et al. Bone marrow and plasma FGF-23 in heart failure patients: novel insights into the heart-bone axis. ESC Heart Fail. 2019;6(3):536–544.
doi: 10.1002/ehf2.12416
45. Elzayat RS, Bahbah WA, Elzaiat RS, Elgazzar BA. Fibroblast growth factor 23 in children with or without heart failure: a prospective study. BMJ Paediatr Open. 2023;7(1):e001753.
doi: 10.1136/bmjpo-2022-001753
46. Roy C, Lejeune S, Slimani A, et al. Fibroblast growth factor 23: a biomarker of fibrosis and prognosis in heart failure with preserved ejection fraction. ESC Heart Fail.
2020;7(5):2494–2507. doi: 10.1002/ehf2.12816
47. Hofer F, Hammer A, Pailer U, et al. Relationship of Fibroblast Growth Factor 23 With Hospitalization for Heart Failure and Cardiovascular Outcomes in Patients Undergoing Cardiac Surgery. J Am Heart Assoc. 2023;12(5):e027875. doi: 10.1161/JAHA.122.027875
48. Binnenmars SH, Hoogslag GE, Yeung SMH, et al. Fibroblast Growth Factor 23 and Risk of New Onset Heart Failure With Preserved or Reduced Ejection Fraction: The PREVEND Study. J Am Heart Assoc. 2022;11(15):e024952. doi: 10.1161/JAHA.121.024952
49. Oniszczuk A, Kaczmarek A, Kaczmarek M, et al. Sclerostin as a biomarker of physical exercise in osteoporosis: A narrative review. Front Endocrinol (Lausanne). 2022;(13):954895. doi: 10.3389/fendo.2022.954895
50. Jaśkiewicz Ł, Chmielewski G, Kuna J, et al. The Role of Sclerostin in Rheumatic Diseases: A Review. J Clin Med. 2023;12(19):6248. doi: 10.3390/jcm12196248
51. Sanabria-de la Torre R, González-Salvatierra S, García-Fontana C, et al. Exploring the Role of Sclerostin as a Biomarker of Cardiovascular Disease and Mortality: A Scoping Review. Int J Environ Res Public Health. 2022;19(23):15981. doi: 10.3390/ijerph192315981
52. Vasiliadis ES, Evangelopoulos DS, Kaspiris A, et al. Sclerostin and Its Involvement in the Pathogenesis of Idiopathic Scoliosis. J Clin Med. 2021;10(22):5286.
doi: 10.3390/jcm10225286
53. Maeda K, Kobayashi Y, Koide M, et al. The Regulation of Bone Metabolism and Disorders by Wnt Signaling. Int J Mol Sci. 2019;20(22):5525. doi: 10.3390/ijms20225525
54. Tu X, Delgado-Calle J, Condon KW, et al. Osteocytes mediate the anabolic actions of canonical Wnt/β-catenin signaling in bone. Proc Natl Acad Sci U S A. 2015;112(5):E478–E486. doi: 10.1073/pnas.1409857112
55. Daniele G, Winnier D, Mari A, et al. Sclerostin and Insulin Resistance in Prediabetes: Evidence of a Cross Talk Between Bone and Glucose Metabolism. Diabetes Care. 2015;38(8):1509–1517. doi: 10.2337/dc14-2989
56. Matsui S, Yasui T, Kasai K, et al. Increase in circulating sclerostin at the early stage of menopausal transition in Japanese women. Maturitas. 2016;(83):72–77.
doi: 10.1016/j.maturitas.2015.10.001
57. Mackey RH, Venkitachalam L, Sutton-Tyrrell K. Calcifications, arterial stiffness and atherosclerosis. Adv Cardiol. 2007;(44):234–244. doi: 10.1159/000096744
58. Sabancilar I, Unsal V, Demir F, et al. Does oxidative status affect serum sclerostin levels in patients with type 2 diabetes mellitus? Folia Med (Plovdiv). 2023;65(1):46–52.
doi: 10.3897/folmed.65.e72953
59. Golledge J, Thanigaimani S. Role of Sclerostin in Cardiovascular Disease. Arterioscler Thromb Vasc Biol. 2022;42(7):e187–e202. doi: 10.1161/ATVBAHA.122.317635
60. Frysz M, Gergei I, Scharnagl H, et al. Circulating Sclerostin Levels Are Positively Related to Coronary Artery Disease Severity and Related Risk Factors. J Bone Miner Res. 2022;37(2):273–284. doi: 10.1002/jbmr.4467
Авторы
А.М. Алиева*, Е.В. Резник, И.А. Котикова, И.Г. Никитин
Российский национальный исследовательский медицинский университет им. Н.И. Пирогова, Москва, Россия
*amisha_alieva@mail.ru
Pirogov Russian National Research Medical University, Moscow, Russia
*amisha_alieva@mail.ru
Российский национальный исследовательский медицинский университет им. Н.И. Пирогова, Москва, Россия
*amisha_alieva@mail.ru
________________________________________________
Pirogov Russian National Research Medical University, Moscow, Russia
*amisha_alieva@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.